Get the Stockscreener App
184.94
0.04%
0.08
Pre-market:
184.95
0.010
+0.01%
Overview
News
Price History
Option Chain
Financials
Why NVDA Down?
Discussions
Forecast
Stock Split
Dividend History
Nvidia Corp stock is traded at $184.94, with a volume of 137.07M.
It is up +0.04% in the last 24 hours and up +5.67% over the past month.
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence to run large language models. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
See More
Previous Close:
$184.86
Open:
$183.22
24h Volume:
137.07M
Relative Volume:
0.75
Market Cap:
$4.49T
Revenue:
$187.14B
Net Income/Loss:
$99.20B
P/E Ratio:
45.81
EPS:
4.0375
Net Cash Flow:
$77.32B
1W Performance:
-1.69%
1M Performance:
+5.67%
6M Performance:
+12.14%
1Y Performance:
+36.08%
1-Day Range:
$183.02
$187.12
1-Week Range:
$183.02
$192.17
52-Week Range:
$86.62
$212.19
Nvidia Corp Stock (NVDA) Company Profile
Name
Nvidia Corp
Sector
Industry
Phone
408-486-2000
Address
2788 SAN TOMAS EXPRESSWAY, SANTA CLARA, CA
Compare NVDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVDA
Nvidia Corp
|
184.94 | 4.49T | 187.14B | 99.20B | 77.32B | 4.0375 |
|
TSM
Taiwan Semiconductor Manufacturing Adr
|
331.77 | 1.68T | 115.71B | 50.52B | 30.27B | 9.7574 |
|
AVGO
Broadcom Inc
|
352.21 | 1.64T | 63.89B | 23.13B | 26.91B | 4.7608 |
|
MU
Micron Technology Inc
|
345.87 | 388.40B | 42.31B | 11.91B | 4.65B | 10.52 |
|
AMD
Advanced Micro Devices Inc
|
207.69 | 330.77B | 32.03B | 3.13B | 5.45B | 2.0235 |
Nvidia Corp Stock (NVDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-25 | Resumed | Raymond James | Strong Buy |
| Nov-20-25 | Reiterated | Barclays | Overweight |
| Nov-20-25 | Reiterated | Bernstein | Outperform |
| Nov-20-25 | Reiterated | Citigroup | Buy |
| Nov-20-25 | Reiterated | Deutsche Bank | Hold |
| Nov-20-25 | Reiterated | JP Morgan | Overweight |
| Nov-20-25 | Reiterated | Jefferies | Buy |
| Nov-20-25 | Reiterated | KeyBanc Capital Markets | Overweight |
| Nov-20-25 | Reiterated | Mizuho | Outperform |
| Nov-20-25 | Reiterated | Morgan Stanley | Overweight |
| Nov-20-25 | Reiterated | Robert W. Baird | Outperform |
| Nov-20-25 | Reiterated | Susquehanna | Positive |
| Nov-20-25 | Reiterated | The Benchmark Company | Buy |
| Nov-20-25 | Reiterated | Truist | Buy |
| Nov-13-25 | Reiterated | Oppenheimer | Outperform |
| Nov-04-25 | Reiterated | Jefferies | Buy |
| Oct-29-25 | Reiterated | DA Davidson | Buy |
| Oct-15-25 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-09-25 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-30-25 | Reiterated | Citigroup | Buy |
| Sep-30-25 | Reiterated | KeyBanc Capital Markets | Overweight |
| Sep-25-25 | Reiterated | Barclays | Overweight |
| Sep-23-25 | Reiterated | Evercore ISI | Outperform |
| Sep-11-25 | Upgrade | DA Davidson | Neutral → Buy |
| Sep-08-25 | Reiterated | Citigroup | Buy |
| Aug-28-25 | Reiterated | Bernstein | Outperform |
| Aug-28-25 | Reiterated | BofA Securities | Buy |
| Aug-28-25 | Reiterated | Citigroup | Buy |
| Aug-28-25 | Reiterated | DA Davidson | Neutral |
| Aug-28-25 | Reiterated | JP Morgan | Overweight |
| Aug-28-25 | Reiterated | Jefferies | Buy |
| Aug-28-25 | Reiterated | KeyBanc Capital Markets | Overweight |
| Aug-28-25 | Reiterated | Morgan Stanley | Overweight |
| Aug-28-25 | Reiterated | Oppenheimer | Outperform |
| Aug-28-25 | Reiterated | Rosenblatt | Buy |
| Aug-28-25 | Reiterated | The Benchmark Company | Buy |
| Aug-28-25 | Reiterated | Truist | Buy |
| Aug-28-25 | Reiterated | Wolfe Research | Outperform |
| Aug-22-25 | Reiterated | Evercore ISI | Outperform |
| Aug-21-25 | Reiterated | UBS | Buy |
| Jul-30-25 | Reiterated | Morgan Stanley | Overweight |
| Jul-16-25 | Reiterated | Needham | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Jun-25-25 | Reiterated | Loop Capital | Buy |
| May-29-25 | Upgrade | Summit Insights | Hold → Buy |
| May-29-25 | Reiterated | TD Cowen | Buy |
| Apr-30-25 | Initiated | Seaport Research Partners | Sell |
| Apr-16-25 | Reiterated | BofA Securities | Buy |
| Apr-16-25 | Reiterated | Raymond James | Strong Buy |
| Apr-03-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-27-25 | Downgrade | Summit Insights | Buy → Hold |
| Nov-21-24 | Reiterated | Barclays | Overweight |
| Nov-21-24 | Reiterated | Evercore ISI | Outperform |
| Nov-21-24 | Reiterated | Goldman | Buy |
| Nov-21-24 | Reiterated | JP Morgan | Overweight |
| Nov-21-24 | Reiterated | Needham | Buy |
| Nov-21-24 | Reiterated | Robert W. Baird | Outperform |
| Nov-21-24 | Reiterated | TD Cowen | Buy |
| Nov-21-24 | Reiterated | The Benchmark Company | Buy |
| Nov-21-24 | Reiterated | Truist | Buy |
| Nov-21-24 | Reiterated | Wells Fargo | Overweight |
| Nov-14-24 | Reiterated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | Redburn Atlantic | Buy |
| Oct-18-24 | Reiterated | BofA Securities | Buy |
| Oct-11-24 | Reiterated | Goldman | Buy |
| Sep-18-24 | Initiated | William Blair | Outperform |
| Aug-29-24 | Reiterated | Needham | Buy |
| Aug-19-24 | Reiterated | Goldman | Buy |
| Aug-06-24 | Upgrade | New Street | Neutral → Buy |
| Jul-15-24 | Reiterated | TD Cowen | Buy |
| Jul-12-24 | Reiterated | The Benchmark Company | Buy |
| Jul-09-24 | Reiterated | KeyBanc Capital Markets | Overweight |
| Jul-08-24 | Reiterated | UBS | Buy |
| Jul-05-24 | Downgrade | New Street | Buy → Neutral |
| Jul-01-24 | Reiterated | Morgan Stanley | Overweight |
| Jun-18-24 | Reiterated | Rosenblatt | Buy |
| Jun-03-24 | Reiterated | BofA Securities | Buy |
| May-24-24 | Downgrade | DZ Bank | Buy → Hold |
| May-23-24 | Reiterated | Craig Hallum | Buy |
| May-23-24 | Reiterated | Deutsche Bank | Hold |
| May-23-24 | Reiterated | Evercore ISI | Outperform |
| May-23-24 | Reiterated | Goldman | Buy |
| May-23-24 | Reiterated | JP Morgan | Overweight |
| May-23-24 | Reiterated | Jefferies | Buy |
| May-23-24 | Reiterated | KeyBanc Capital Markets | Overweight |
| May-23-24 | Reiterated | Mizuho | Buy |
| May-23-24 | Reiterated | Morgan Stanley | Overweight |
| May-23-24 | Reiterated | Needham | Buy |
| May-23-24 | Reiterated | Piper Sandler | Overweight |
| May-23-24 | Reiterated | Raymond James | Strong Buy |
| May-23-24 | Reiterated | Stifel | Buy |
| May-23-24 | Reiterated | Susquehanna | Positive |
| May-23-24 | Reiterated | TD Cowen | Buy |
| May-23-24 | Reiterated | The Benchmark Company | Buy |
| May-23-24 | Reiterated | Truist | Buy |
| May-23-24 | Reiterated | UBS | Buy |
| May-23-24 | Reiterated | Wells Fargo | Overweight |
| May-23-24 | Reiterated | Wolfe Research | Outperform |
| May-20-24 | Reiterated | Barclays | Overweight |
| May-20-24 | Reiterated | Robert W. Baird | Outperform |
| May-20-24 | Reiterated | Stifel | Buy |
| May-20-24 | Reiterated | Susquehanna | Positive |
| May-13-24 | Initiated | Jefferies | Buy |
| Apr-16-24 | Initiated | Evercore ISI | Outperform |
| Apr-11-24 | Reiterated | Raymond James | Strong Buy |
| Apr-10-24 | Reiterated | Morgan Stanley | Overweight |
| Apr-08-24 | Reiterated | KeyBanc Capital Markets | Overweight |
| Mar-22-24 | Reiterated | UBS | Buy |
| Mar-21-24 | Reiterated | TD Cowen | Outperform |
| Mar-07-24 | Reiterated | Mizuho | Buy |
| Feb-22-24 | Reiterated | BofA Securities | Buy |
| Feb-22-24 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-22-24 | Reiterated | Citigroup | Buy |
| Feb-22-24 | Reiterated | DA Davidson | Neutral |
| Feb-22-24 | Reiterated | Deutsche Bank | Hold |
| Feb-22-24 | Reiterated | Goldman | Buy |
| Feb-22-24 | Reiterated | HSBC Securities | Buy |
| Feb-22-24 | Reiterated | JP Morgan | Overweight |
| Feb-22-24 | Reiterated | Jefferies | Buy |
| Feb-22-24 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-22-24 | Reiterated | Mizuho | Buy |
| Feb-22-24 | Reiterated | Morgan Stanley | Overweight |
| Feb-22-24 | Reiterated | Needham | Buy |
| Feb-22-24 | Reiterated | Stifel | Buy |
| Feb-22-24 | Reiterated | TD Cowen | Outperform |
| Feb-22-24 | Reiterated | The Benchmark Company | Buy |
| Feb-22-24 | Reiterated | Truist | Buy |
| Feb-22-24 | Reiterated | UBS | Buy |
| Feb-22-24 | Reiterated | Wedbush | Outperform |
| Feb-22-24 | Reiterated | Wolfe Research | Outperform |
| Feb-16-24 | Initiated | Loop Capital | Buy |
| Feb-15-24 | Reiterated | Piper Sandler | Overweight |
| Feb-13-24 | Reiterated | UBS | Buy |
| Feb-05-24 | Reiterated | Goldman | Buy |
| Jan-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-03-24 | Initiated | DA Davidson | Neutral |
| Nov-22-23 | Reiterated | BMO Capital Markets | Outperform |
| Nov-22-23 | Reiterated | Bernstein | Outperform |
| Nov-22-23 | Reiterated | BofA Securities | Buy |
| Nov-22-23 | Downgrade | Edward Jones | Buy → Hold |
| Nov-22-23 | Reiterated | Goldman | Buy |
| Nov-22-23 | Reiterated | JP Morgan | Overweight |
| Nov-22-23 | Reiterated | Mizuho | Buy |
| Nov-22-23 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-23 | Reiterated | Rosenblatt | Buy |
| Nov-22-23 | Reiterated | Truist | Buy |
| Nov-22-23 | Reiterated | UBS | Buy |
| Nov-22-23 | Reiterated | Wells Fargo | Overweight |
| Oct-11-23 | Reiterated | TD Cowen | Outperform |
| Aug-24-23 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Aug-24-23 | Reiterated | Rosenblatt | Buy |
| Aug-24-23 | Upgrade | Stifel | Hold → Buy |
| Aug-24-23 | Reiterated | TD Cowen | Outperform |
| Aug-21-23 | Reiterated | HSBC Securities | Buy |
| Aug-21-23 | Reiterated | KeyBanc Capital Markets | Overweight |
| Aug-09-23 | Reiterated | Stifel | Hold |
| Jul-24-23 | Reiterated | Mizuho | Buy |
| Jul-20-23 | Initiated | Wolfe Research | Outperform |
| Jul-17-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Reiterated | Truist | Buy |
| Jul-11-23 | Reiterated | KeyBanc Capital Markets | Overweight |
| Jun-30-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jun-16-23 | Reiterated | Morgan Stanley | Overweight |
| May-25-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-25-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-25-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-19-23 | Reiterated | BofA Securities | Buy |
| Apr-18-23 | Upgrade | HSBC Securities | Reduce → Buy |
| Mar-27-23 | Reiterated | UBS | Buy |
| Mar-21-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Mar-17-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-23 | Resumed | Raymond James | Strong Buy |
| Feb-23-23 | Upgrade | Goldman | Neutral → Buy |
| Feb-21-23 | Reiterated | BMO Capital Markets | Outperform |
| Feb-16-23 | Downgrade | DZ Bank | Buy → Sell |
| Jan-23-23 | Reiterated | Truist | Buy |
| Dec-19-22 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | HSBC Securities | Reduce |
| Nov-17-22 | Upgrade | Summit Insights | Hold → Buy |
| Nov-16-22 | Resumed | Credit Suisse | Outperform |
| Sep-08-22 | Initiated | Stifel | Hold |
| Sep-02-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-08-22 | Downgrade | Craig Hallum | Buy → Hold |
| Jul-13-22 | Reiterated | Susquehanna | Positive |
| May-26-22 | Resumed | The Benchmark Company | Buy |
| May-03-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Upgrade | New Street | Neutral → Buy |
| Apr-11-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-15-22 | Reiterated | Cowen | Outperform |
| Mar-07-22 | Resumed | Goldman | Neutral |
| Feb-17-22 | Downgrade | Summit Insights | Buy → Hold |
| Nov-18-21 | Reiterated | BofA Securities | Buy |
| Nov-18-21 | Reiterated | Craig Hallum | Buy |
| Nov-18-21 | Reiterated | Deutsche Bank | Hold |
| Nov-18-21 | Reiterated | JP Morgan | Overweight |
| Nov-18-21 | Reiterated | Jefferies | Buy |
| Nov-18-21 | Reiterated | KeyBanc Capital Markets | Overweight |
| Nov-18-21 | Reiterated | Mizuho | Buy |
| Nov-18-21 | Reiterated | Needham | Buy |
| Nov-18-21 | Reiterated | Piper Sandler | Overweight |
| Nov-18-21 | Reiterated | Raymond James | Strong Buy |
| Nov-18-21 | Reiterated | Truist | Buy |
| Nov-15-21 | Reiterated | Citigroup | Buy |
| Nov-15-21 | Reiterated | UBS | Buy |
| Nov-12-21 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-22-21 | Upgrade | Summit Insights | Sell → Buy |
| Oct-05-21 | Reiterated | KeyBanc Capital Markets | Overweight |
| Sep-17-21 | Reiterated | BofA Securities | Buy |
| Aug-20-21 | Resumed | The Benchmark Company | Buy |
| Aug-19-21 | Downgrade | Summit Insights | Hold → Sell |
| Aug-12-21 | Reiterated | Evercore ISI | Outperform |
| Aug-12-21 | Reiterated | UBS | Buy |
| Aug-12-21 | Reiterated | Wells Fargo | Overweight |
| Aug-04-21 | Reiterated | Rosenblatt | Buy |
| Jul-15-21 | Reiterated | Mizuho | Buy |
| Jul-08-21 | Reiterated | Oppenheimer | Outperform |
| Jul-06-21 | Reiterated | KeyBanc Capital Markets | Overweight |
| Jul-01-21 | Reiterated | BMO Capital Markets | Outperform |
| Jun-22-21 | Reiterated | Raymond James | Strong Buy |
| Jun-18-21 | Reiterated | BofA Securities | Buy |
| Jun-17-21 | Reiterated | Jefferies | Buy |
| May-27-21 | Reiterated | BofA Securities | Buy |
| May-27-21 | Reiterated | Cowen | Outperform |
| May-27-21 | Upgrade | Craig Hallum | Hold → Buy |
| May-20-21 | Resumed | KeyBanc Capital Markets | Sector Weight |
| May-05-21 | Initiated | Robert W. Baird | Outperform |
| Apr-15-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-21 | Reiterated | Cowen | Outperform |
| Apr-13-21 | Reiterated | Rosenblatt | Buy |
| Feb-25-21 | Reiterated | Cowen | Outperform |
| Feb-22-21 | Reiterated | Susquehanna | Positive |
| Feb-03-21 | Upgrade | New Street | Sell → Neutral |
| Nov-12-20 | Reiterated | Cascend Securities | Buy |
| Oct-09-20 | Downgrade | New Street | Neutral → Sell |
| Oct-06-20 | Reiterated | BMO Capital Markets | Outperform |
| Oct-02-20 | Reiterated | Wedbush | Outperform |
| Sep-15-20 | Reiterated | Needham | Buy |
| Sep-02-20 | Reiterated | BofA Securities | Buy |
| Sep-02-20 | Reiterated | Credit Suisse | Outperform |
| Sep-02-20 | Reiterated | Goldman | Buy |
| Sep-02-20 | Reiterated | Mizuho | Buy |
| Sep-02-20 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-02-20 | Reiterated | The Benchmark Company | Buy |
| Aug-20-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Aug-20-20 | Reiterated | Needham | Buy |
| Aug-20-20 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-20-20 | Reiterated | Raymond James | Outperform |
| Aug-20-20 | Reiterated | Rosenblatt | Buy |
| Aug-20-20 | Reiterated | Susquehanna | Positive |
| Aug-20-20 | Reiterated | Truist | Buy |
| Aug-20-20 | Reiterated | Wedbush | Outperform |
| Aug-20-20 | Reiterated | Wells Fargo | Overweight |
View All
Nvidia Corp Stock (NVDA) Latest News
Nvidia Denies Upfront Payments, Making H200 Chips Easier to Buy - TipRanks
Nvidia officials expressed intent to offer S. Korea priority supply of next-gen GPUs: vice minister - Yonhap News Agency
AI healthcare enters a golden era of development! NVIDIA and Eli Lilly and Co invest in AI-driven drug discovery, while OpenAI acquires healthcare startup Torch. - 富途牛牛
Nvidia says no upfront payment needed for its H200 chips - Reuters
Could Jensen Huang and Nvidia chart Oregon State football’s future? Beavers’ new coach is leaning in - OregonLive.com
Why Serve Robotics (SERV) Is Up 13.1% After NVIDIA CEO Jensen Huang’s “Physical AI” Endorsement - Yahoo Finance
NVIDIA And Lilly Announce Co-Innovation AI Lab To Reinvent Drug Discovery In The Age Of AI - Pulse 2.0
Stock Market Today, Jan. 12: CoreWeave Surges After CEO Rebuttal Restores Confidence in AI Cloud Model - The Motley Fool
Google-Parent Alphabet Becomes Newest $4 Trillion Company, Joining Nvidia - The Wall Street Journal
Thermo Fisher partners with NVIDIA to develop AI-powered lab solutions - Investing.com
JPM26, Day 1: Stock market titans Lilly, Nvidia expand team-up with AI co-innovation lab - Fierce Biotech
Nvidia, US firm Eli Lilly to launch $1b AI co-innovation lab - Tech in Asia
Nvidia Stock: Why the Chip Maker Is Down Recently—and What Can Reignite It - Barron's
Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab - Reuters
Prediction: Nvidia Will Be Worth $7 Trillion by the End of 2026 - Yahoo Finance
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab to Reinvent Drug Discovery - HIT Consultant
JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership - Yahoo Finance
Nvidia and Eli Lilly launch Co-Innovation AI Lab to advance drug discovery - Proactive financial news
Here’s What Wall Street Thinks About NVIDIA Corporation (NVDA) - Insider Monkey
Google-parent Alphabet joins $4 trillion club with Nvidia, Apple and Microsoft: 4 key things that helped - Times of India
With Nvidia in the Limelight, Examine This Exciting ETF - ETF Database
Here's What Wall Street Thinks About NVIDIA Corporation (NVDA) - Finviz
AlphaTON expands exposure to decentralized Telegram-based Cocoon AI with NVIDIA deal - The Block
NVIDIA and Eli Lilly and Company Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI - marketscreener.com
Eli Lilly and Nvidia plan new AI lab to speed drug discovery - qz.com
The Convergence of Silicon and Science: Eli Lilly and Nvidia Unveil $1 Billion AI Co-Innovation Lab at JPM26 - FinancialContent
Nvidia, Eli Lilly announce $1 billion investment in AI drug discovery lab - Yahoo Finance
At CES, NVIDIA Rubin and AMD “Helios” Made Memory the Future of AI - The Futurum Group
Nvidia and Lilly form $1 billion AI partnership for drug discovery By Investing.com - Investing.com South Africa
Nvidia and Lilly form $1 billion AI partnership for drug discovery - Investing.com Canada
Nvidia to invest US$1 bil in AI drug lab with Eli Lilly - The Edge Singapore
Alphabet Becomes Newest $4 Trillion Company, Joining Nvidia and Apple - The Wall Street Journal
EndoQuest expands collaboration with NVIDIA to power next-generation endoluminal robotic surgery - Medical Economics
AI21 Labs denies Nvidia acquisition talksGlobes - Globes - Israel Business News
New heat sinks cool NVIDIA Jetson Thor edge modules - IT Brief New Zealand
Nvidia and Eli Lilly collaborate on AI laboratory - medwatch.com
Lilly, NVIDIA launch $1 billion AI lab for drug discovery - Investing.com
From Training AI to Designing Chips: Nvidia's Next Platform Play - The Motley Fool
Nvidia, Eli Lilly to Launch AI-Powered Co-Innovation Lab -- Update - marketscreener.com
Nvidia, Eli Lilly announce AI co-innovation lab - TipRanks
Eli Lilly, Nvidia to launch AI co-innovation lab for drug discovery - Seeking Alpha
CoreWeave to add NVIDIA Rubin platform to its AI cloud in 2026 - ROI-NJ
The Zacks Analyst Blog Highlights NVIDIA, Alphabet, Amazon.com and CBL & Associates Properties - Yahoo Finance Singapore
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI - The Globe and Mail
The Zacks Analyst Blog Highlights NVIDIA, Micron Technology, Credo Technology and Amtech Systems - Yahoo Finance Singapore
NVIDIA and Eli Lilly Launch First AI Co-Innovation Lab to Revolutionize Drug Discovery - Quiver Quantitative
Nvidia and Lilly announce co-innovation AI lab to reinvent drug discovery in the age of AI - marketscreener.com
Nvidia Stock Wobbles Even as CEO Flags 'Very High' H200 Demand - Yahoo Finance UK
Nvidia And Lilly Announce Co-Innovation AI Lab To Reinvent Drug Discovery In The Age Of AI - TradingView — Track All Markets
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery - NVIDIA Newsroom
Nvidia and Microsoft back AI breakthrough for gene therapies - Financial Times
Nvidia Corp Stock (NVDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
3.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):